We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+4.48%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$329M
AUM Growth
-$29.9M
Cap. Flow
-$29.1M
Cap. Flow %
-8.87%
Top 10 Hldgs %
51.54%
Holding
77
New
13
Increased
17
Reduced
12
Closed
16

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$12.2M
2
APLS
Apellis Pharmaceuticals
APLS
+$8.46M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$7.07M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$6.94M
5
GILD icon
Gilead Sciences
GILD
+$6.94M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$40.5M
2
ALKS icon
Alkermes
ALKS
+$16.7M
3
EXEL icon
Exelixis
EXEL
+$10.5M
4
QURE icon
uniQure
QURE
+$8.77M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$8.53M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HCM icon
51
HUTCHMED
HCM
$2.16B
$816K 0.25%
68,000
– –
BEAM icon
52
Beam Therapeutics
BEAM
$3.15B
$750K 0.23%
23,500
– –
PTCT icon
53
PTC Therapeutics
PTCT
$5.99B
$692K 0.21%
17,000
-76,000
-82% -$3.72M
AGIO icon
54
Agios Pharmaceuticals
AGIO
$2.05B
$680K 0.21%
+24,000
New +$597K
PTGX icon
55
Protagonist Therapeutics
PTGX
$9.67B
$549K 0.17%
+19,900
New +$498K
AMLX icon
56
Amylyx Pharmaceuticals
AMLX
$4.14B
$539K 0.16%
+25,000
New +$675K
VTYX
57
DELISTED
Ventyx Biosciences
VTYX
$491K 0.15%
15,000
– –
IOVA icon
58
Iovance Biotherapeutics
IOVA
$3.74B
$457K 0.14%
65,000
+9,000
+16% +$64.4K
ARVN icon
59
Arvinas
ARVN
$604M
$421K 0.13%
17,000
– –
QURE icon
60
uniQure
QURE
$3.44B
$178K 0.05%
15,500
-463,000
-97% -$8.77M
RLMD icon
61
Relmada Therapeutics
RLMD
$482M
$24.7K 0.01%
10,000
– –
ACET icon
62
Adicet Bio
ACET
$84.3M
– –
-9,669
Closed -$890K
ALKS icon
63
Alkermes
ALKS
$8.2B
– –
-593,000
Closed -$16.7M
ASND icon
64
Ascendis Pharma A/S
ASND
$16.4B
– –
-29,400
Closed -$3.15M
AZN icon
65
AstraZeneca
AZN
$255B
– –
-32,500
Closed -$4.51M
BCRX icon
66
BioCryst Pharmaceuticals
BCRX
$2.52B
– –
-57,000
Closed -$475K
CRBU icon
67
Caribou Biosciences
CRBU
$178M
– –
-457,892
Closed -$2.43M
CRSP icon
68
CRISPR Therapeutics
CRSP
$5.74B
– –
-34,200
Closed -$1.55M
EXEL icon
69
Exelixis
EXEL
$13.7B
– –
-543,000
Closed -$10.5M
GMAB icon
70
Genmab
GMAB
$21B
– –
-88,000
Closed -$3.32M
IDYA icon
71
IDEAYA Biosciences
IDYA
$4.03B
– –
-19,000
Closed -$261K
IRWD icon
72
Ironwood Pharmaceuticals
IRWD
$701M
– –
-60,000
Closed -$631K
NVAX icon
73
Novavax
NVAX
$1.49B
– –
-132,500
Closed -$925K
SNY icon
74
Sanofi
SNY
$107B
– –
-143,500
Closed -$7.81M
SGEN
75
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-200,200
Closed -$40.5M
1 2
3
4

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q2 2023 Portfolio in Review

As of Q2 2023, International Biotechnology Trust held 77 positions worth $329M, down 8.3% from $358M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

International Biotechnology Trust withdrew a net $29.1M in Q2 2023, closing 16 positions and reducing 12 holdings. Its most notable exit was Seagen Inc. Common Stock, an estimated $40.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

Against the trend, International Biotechnology Trust opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares worth $6.89M.

  • International Biotechnology Trust's largest Q2 2023 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 67,000 shares worth $6.89M.
  • International Biotechnology Trust added most to Regeneron Pharmaceuticals in Q2 2023, an estimated $12.2M increase.
  • International Biotechnology Trust's biggest Q2 2023 reduction was uniQure, cutting an estimated $8.77M.
  • International Biotechnology Trust fully exited Seagen Inc. Common Stock in Q2 2023, selling an estimated $40.5M.
  • International Biotechnology Trust's ten largest holdings make up 52% of its $329M portfolio in Q2 2023.
  • International Biotechnology Trust opened 13 new positions and closed 16 in Q2 2023.
  • International Biotechnology Trust's portfolio value fell 8.3% quarter-over-quarter to $329M.

Based on International Biotechnology Trust's 13F filing for Q2 2023, filed 8 Aug 2023.